Indica Labs Announces Second January Webinar

Autoimmune diseases affect more than 23.5 million Americans, involving nearly every organ system of the human body. These diseases are characterized by chronic inflammation which leads to organ damage and can have a devastating impact on the health and quality of life of individuals living with these diseases. To better identify common pathways underlying the pathogenesis of autoimmune diseases and to define new therapies, The Accelerating Medicines Partnership® Autoimmune and Immune-Mediated Disease Program (AMP AIM), was launched to investigate Rheumatoid Arthritis (RA, Systemic Lupus Erythematosus (SLE), Psoriatic Disease (PsD), and Sjogren’s Disease (SjD) using single-cell and spatial multi-omics technologies.

To assist in this aim, the AMP AIM network has employed the HALO suite from an Amazon Web Services (AWS) environment to allow for a robust system of data sharing/viewing, histology review, and pathology scoring via HALO Link. Additionally, utilizing the tools found in HALO AI, the network can leverage novel algorithms to better define disease states and classify study participants for selection into specific projects and for advanced imaging modalities. Taken together, the HALO suite of software has enabled the AMP AIM network to better manage and understand the patient populations of this important research network.